NICE GUIDANCE PH48 TOOLKIT DOCUMENT 9: VARENICLINE INFORMATION

MODE OF ACTION

- Varenicline is a nicotinic receptor agonist and antagonist
- It causes dopamine release via its agonist action and alleviates cravings for nicotine and also prevents dopamine release from nicotine in cigarette smoke through its antagonist action
- It is a highly effective treatment for tobacco addiction through both relief of cravings and preventing positive impact from smoking that reinforces the addiction

EFFECTIVENESS & EVIDENCE BASE

- Varenicline is a highly effective tobacco addiction treatment with smokers
- It has been proven to be more effective than NRT and bupropion
- In the EAGLES study¹ (randomised controlled trial) Varenicline was the most effective treatment when compared to NRT and Bupropion at 9-12 weeks

NICE TA123²

- Recommends Varenicline should be prescribed in combination with specialist and behavioural support
- If such support is refused or is not available, this should not preclude treatment with Varenicline

INCLUSION CRITERIA

• Current Smokers, consenting to treatment with Varenicline to Quit Tobacco who are over the age of 18 years

EXCLUSION CRITERIA

- Non-smokers
- Smokers who have had previous serious reaction to Varenicline or any ingredients contained in the products
- Smokers aged under 18 years
- Pregnant women
- Patients with end stage renal failure
- Breastfeeding women



CAUTIONED

• Use in patients with a history of seizures or other conditions that potentially lower the seizure threshold.

If serious neuropsychiatric symptoms occur whilst on varenicline treatment, patients should discontinue varenicline immediately

The following linked documents give access to the Eagle Study, and resources developed by CURE as an example approach to Varenicline treatment.

<u>The Lancet - Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine</u> patch in smokers with and without psychiatric disorders (EAGLES)

CURE Training

REFERENCES

- 1. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30272-0/fulltext
- 2. https://www.nice.org.uk/Guidance/TA123



